France vs Middle East, North Africa, Afghanistan & Pakistan (excluding high income): Access to anti-retroviral drugs, male

France
89.0%
in 2022
Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
22.9%
in 2024
France rank
17th
Middle East, North Africa, Afghanistan & Pakistan (excluding high income) rank
18th

Access to anti-retroviral drugs, male over time

  • France
  • Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
020406080200020122024

How they compare

France currently reports 89.0% against 22.9% in Middle East, North Africa, Afghanistan & Pakistan (excluding high income), a difference of 66.1%.

That makes France's figure about 3.9 times Middle East, North Africa, Afghanistan & Pakistan (excluding high income)'s.

Across all 23 years both countries report, France has been ahead every year.

France ranks 17th and Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 18th of 141 countries.

France has averaged higher in every one of the 3 decades both report.

Head to head by decade

Decade France Middle East, North Africa, Afghanistan & Pakistan (excluding high income) Difference Ahead
2000s 79.8% 3.3% 76.5% France
2010s 86.9% 10.3% 76.6% France
2020s 88.7% 17.7% 71.0% France

Averages of every year both report within each decade.

Frequently asked questions

Which has higher access to anti-retroviral drugs, male, France or Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
France, at 89.0% against 22.9% in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) as of 2022.
What is the difference in access to anti-retroviral drugs, male between France and Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
66.1%, with France ahead.
How many years of comparable data are there for France and Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
23 years are reported by both, from 2000 to 2022.
How do France and Middle East, North Africa, Afghanistan & Pakistan (excluding high income) rank globally for access to anti-retroviral drugs, male?
France ranks 17th and Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 18th of 141 countries.
Where does this data come from?
UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

Share, cite or embed this page

Cite this page

France vs Middle East, North Africa, Afghanistan & Pakistan (excluding high income): Access to anti-retroviral drugs, male. Statizoid, drawing on UNAIDS estimates. Retrieved 19 September 2026, from https://gender.statizoid.com/compare/access-to-anti-retroviral-drugs-male-percent/france/middle-east-north-africa-afghanistan-and-pakistan-excluding-high-income/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/compare/access-to-anti-retroviral-drugs-male-percent/france/middle-east-north-africa-afghanistan-and-pakistan-excluding-high-income/">France vs Middle East, North Africa, Afghanistan & Pakistan (excluding high income): Access to anti-retroviral drugs, male</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.